Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Héctor Hernández-De la Cerda"'
Autor:
Perla Pérez-Treviño, Héctor Hernández-De la Cerda, Jorge Pérez-Treviño, Oscar Raúl Fajardo-Ramírez, Noemí García, Julio Altamirano
Publikováno v:
Translational Oncology, Vol 11, Iss 3, Pp 672-685 (2018)
Patients with breast cancer (BC) overexpressing HER2 (HER2+) are selected for Trastuzumab treatment, which blocks HER2 and improves cancer prognosis. However, HER2+ diagnosis, by the gold standard, immunohistochemistry, could lead to errors, associat
Externí odkaz:
https://doaj.org/article/37c9ba06547d48f7afe141a07c96d79a
Autor:
Jürgen Riedel, Francisco Hernández-Quiroz, Hector Zenil, Santiago Hernández-Orozco, Kourosh Saeb-Parsy, Héctor Hernández De la Cerda
We introduce a numerical and a colour-based risk stratification score to quantify abnormal blood analyte values. The score indicates how removed values of an individual are from considered healthy ranges from the literature or derived from empirical
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5de2903d2138aa43f84acb3f8d30e0e0
https://doi.org/10.1101/2020.02.09.941096
https://doi.org/10.1101/2020.02.09.941096
Autor:
Jorge Pérez-Treviño, Héctor Hernández-De la Cerda, Julio Altamirano, Oscar R. Fajardo-Ramírez, Perla Pérez-Treviño, Noemí García
Publikováno v:
Translational Oncology, Vol 11, Iss 3, Pp 672-685 (2018)
Translational Oncology
Translational Oncology
Patients with breast cancer (BC) overexpressing HER2 (HER2+) are selected for Trastuzumab treatment, which blocks HER2 and improves cancer prognosis. However, HER2+ diagnosis, by the gold standard, immunohistochemistry, could lead to errors, associat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c84915e40562591766131051a1d16614
http://www.sciencedirect.com/science/article/pii/S1936523318300068
http://www.sciencedirect.com/science/article/pii/S1936523318300068